TetraKit Technologies has developed a click chemistry-based radiolabeling platform that enables the efficient labeling of cancer-targeting molecules with radionuclide pairs, specifically fluorine-18 and astatine-211, for theranostic applications. This platform addresses the need for a practical and universal solution in targeted radionuclide therapy, enhancing the production of radiopharmaceuticals for improved cancer diagnosis and treatment.
Funding
$560K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Targeted radionuclide therapy for late-stage metastatic cancer requires efficient methods for attaching radioactive atoms to cancer-targeting molecules. Existing radiopharmaceutical production methods lack a practical and universal solution for labeling molecules with radionuclide pairs for theranostic applications.
Solution
TetraKit Technologies offers a click chemistry-based radiochemical platform that enables the labeling of cancer-targeting molecules with radionuclide pairs for theranostic applications. The platform focuses on fluorine-18 for PET imaging and astatine-211 for targeted alpha-radionuclide therapy. By providing a universal labeling platform, TetraKit aims to improve patient care and disease outcomes through enhanced radiopharmaceutical production. The technology facilitates the creation of next-generation theranostic radiopharmaceuticals, improving both cancer diagnosis via nuclear imaging and treatment through selective destruction of cancerous tissue.
Target Audience
The primary customers are researchers and clinicians in the fields of nuclear medicine and oncology who are developing and utilizing radiopharmaceuticals for cancer diagnosis and therapy.
Features
- Click chemistry-based radiolabeling platform for efficient attachment of radionuclides to targeting molecules
- Focus on fluorine-18 and astatine-211 radionuclide pairs for PET imaging and targeted alpha-radionuclide therapy
- Platform enables the creation of radiopharmaceuticals for both diagnostic and therapeutic applications (theranostics)
- Astatine-211 based alpha-therapy for treatment of late-stage metastatic cancer